Cargando…
Protamine-Based Strategies for RNA Transfection
Protamine is a natural cationic peptide mixture mostly known as a drug for the neutralization of heparin and as a compound in formulations of slow-release insulin. Protamine is also used for cellular delivery of nucleic acids due to opposite charge-driven coupling. This year marks 60 years since the...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8231816/ https://www.ncbi.nlm.nih.gov/pubmed/34198550 http://dx.doi.org/10.3390/pharmaceutics13060877 |
_version_ | 1783713501018062848 |
---|---|
author | Jarzebska, Natalia Teresa Mellett, Mark Frei, Julia Kündig, Thomas M. Pascolo, Steve |
author_facet | Jarzebska, Natalia Teresa Mellett, Mark Frei, Julia Kündig, Thomas M. Pascolo, Steve |
author_sort | Jarzebska, Natalia Teresa |
collection | PubMed |
description | Protamine is a natural cationic peptide mixture mostly known as a drug for the neutralization of heparin and as a compound in formulations of slow-release insulin. Protamine is also used for cellular delivery of nucleic acids due to opposite charge-driven coupling. This year marks 60 years since the first use of Protamine as a transfection enhancement agent. Since then, Protamine has been broadly used as a stabilization agent for RNA delivery. It has also been involved in several compositions for RNA-based vaccinations in clinical development. Protamine stabilization of RNA shows double functionality: it not only protects RNA from degradation within biological systems, but also enhances penetration into cells. A Protamine-based RNA delivery system is a flexible and versatile platform that can be adjusted according to therapeutic goals: fused with targeting antibodies for precise delivery, digested into a cell penetrating peptide for better transfection efficiency or not-covalently mixed with functional polymers. This manuscript gives an overview of the strategies employed in protamine-based RNA delivery, including the optimization of the nucleic acid’s stability and translational efficiency, as well as the regulation of its immunostimulatory properties from early studies to recent developments. |
format | Online Article Text |
id | pubmed-8231816 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-82318162021-06-26 Protamine-Based Strategies for RNA Transfection Jarzebska, Natalia Teresa Mellett, Mark Frei, Julia Kündig, Thomas M. Pascolo, Steve Pharmaceutics Review Protamine is a natural cationic peptide mixture mostly known as a drug for the neutralization of heparin and as a compound in formulations of slow-release insulin. Protamine is also used for cellular delivery of nucleic acids due to opposite charge-driven coupling. This year marks 60 years since the first use of Protamine as a transfection enhancement agent. Since then, Protamine has been broadly used as a stabilization agent for RNA delivery. It has also been involved in several compositions for RNA-based vaccinations in clinical development. Protamine stabilization of RNA shows double functionality: it not only protects RNA from degradation within biological systems, but also enhances penetration into cells. A Protamine-based RNA delivery system is a flexible and versatile platform that can be adjusted according to therapeutic goals: fused with targeting antibodies for precise delivery, digested into a cell penetrating peptide for better transfection efficiency or not-covalently mixed with functional polymers. This manuscript gives an overview of the strategies employed in protamine-based RNA delivery, including the optimization of the nucleic acid’s stability and translational efficiency, as well as the regulation of its immunostimulatory properties from early studies to recent developments. MDPI 2021-06-14 /pmc/articles/PMC8231816/ /pubmed/34198550 http://dx.doi.org/10.3390/pharmaceutics13060877 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Jarzebska, Natalia Teresa Mellett, Mark Frei, Julia Kündig, Thomas M. Pascolo, Steve Protamine-Based Strategies for RNA Transfection |
title | Protamine-Based Strategies for RNA Transfection |
title_full | Protamine-Based Strategies for RNA Transfection |
title_fullStr | Protamine-Based Strategies for RNA Transfection |
title_full_unstemmed | Protamine-Based Strategies for RNA Transfection |
title_short | Protamine-Based Strategies for RNA Transfection |
title_sort | protamine-based strategies for rna transfection |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8231816/ https://www.ncbi.nlm.nih.gov/pubmed/34198550 http://dx.doi.org/10.3390/pharmaceutics13060877 |
work_keys_str_mv | AT jarzebskanataliateresa protaminebasedstrategiesforrnatransfection AT mellettmark protaminebasedstrategiesforrnatransfection AT freijulia protaminebasedstrategiesforrnatransfection AT kundigthomasm protaminebasedstrategiesforrnatransfection AT pascolosteve protaminebasedstrategiesforrnatransfection |